Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
| Autor: | Ya-Hui Wang, Chao-Hsien Chen, Chih-Cheng Lai, Yu-Chi Kuo, Cheng-Yi Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine law.invention chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Immunology and Allergy Medicine 030212 general & internal medicine Clinical efficacy Child Randomized Controlled Trials as Topic Triazines virus diseases General Medicine Middle Aged Viral Load QR1-502 Treatment Outcome Infectious Diseases Meta-analysis Female Adult Dibenzothiepins Microbiology (medical) medicine.medical_specialty Oseltamivir Adolescent Pyridones Morpholines 030106 microbiology Placebo Lower risk Antiviral Agents Microbiology Young Adult 03 medical and health sciences Internal medicine Influenza Human Humans Adverse effect General Immunology and Microbiology business.industry Influenza a Influenza chemistry Baloxavir business |
| Zdroj: | Journal of Microbiology, Immunology and Infection, Vol 54, Iss 5, Pp 865-875 (2021) |
| ISSN: | 1684-1182 |
| Popis: | Purpose The aim of this meta-analysis is to compare the clinical efficacy and safety of baloxavir with other anti-influenza agents or placebo in the treatment of influenza. Methods PubMed, Embase, Web of Science, Google Scholar, Scopus, CINAHL, Cochrane databases and clinical registration were searched from inception until February 15 2021 for relevant randomized controlled trials (RCTs). Only phase 3 RCTs evaluating the usefulness of baloxavir in the treatment of influenza were included. Results Three RCTs enrolling 3771 patients (baloxavir group, n = 1451; oseltamivir group, n = 1288; placebo group, n = 1032) were included. Compared with oseltamivir, baloxavir had an insignificantly shorter time to the alleviation of symptoms (mean difference [MD], −1.29 h; 95% CI, −6.80 to 4.21; I2 = 0%). In contrast, baloxavir had a significantly shorter time to the alleviation of symptoms than placebo (MD, −26.32 h; 95% CI, −33.78 to −18.86; I2 = 0%). Baloxavir was associated with a significant decline in influenza virus titers and viral RNA load compared to oseltamivir and placebo. Baloxavir was associated with a lower risk of any adverse events than oseltamivir (OR, 0.82; 95% CI, 0.69–0.98; I2 = 0%) and placebo (OR, 0.79; 95% CI, 0.66–0.96; I2 = 0%). Conclusions The findings of this meta-analysis suggested that baloxavir is superior to placebo in the treatment of influenza in both clinical outcome and virological response. Moreover, baloxavir was found to have a better virological response than oseltamivir and to be as effective as oseltamivir clinically. Compared with oseltamivir and placebo, baloxavir appears to be a relatively safe anti-influenza agent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|